Abstracts Archive - Page 2178 of 2607 - ACR Meeting Abstracts

Abstract Number: 824 • 2014 ACR/ARHP Annual Meeting
Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus
Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom
Background/Purpose Glucocorticoid (GC) therapy is known to increase the risk of new-onset type 2 diabetes mellitus (DM). Furthermore, GC therapy increases blood glucose in diabetic…
Abstract Number: 825 • 2014 ACR/ARHP Annual Meeting
Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time, and How High Are They?
Elizabeth V. Arkema¹, Johan Askling² and the ARTIS Study group³, ¹Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ²Clinical Epidemiology Unit, Karolinska Institutet, Stockholm, Sweden, ³Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden
Background/Purpose: The rheumatoid arthritis (RA) population starting tumor necrosis factor inhibitors (TNFi) today is much different in terms of accumulated and concurrent disease activity and…
Abstract Number: 823 • 2014 ACR/ARHP Annual Meeting
Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol
Alina Soare¹, Carina Mihai², Ana Maria Gherghe², Rucsandra Dobrota², Raida Oneata², Simona Pintilie², Mihaela Milicescu², Ioan Ancuta², Andrei Martin², Mariana Sasu², Claudia Ciofu², Liviu Macovei², Victor Stoica² and Mihai Bojinca², ¹internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania, ²Internal Medicine and Rheumatology, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania
Background/Purpose Tuberculosis (TB) is a major concern in patients receiving TNF inhibitors (TNFi), especially in countries with a high TB burden. Careful TB screening is…
Abstract Number: 822 • 2014 ACR/ARHP Annual Meeting
Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study
Deepan Dalal¹, Maureen Dubreuil^2,3, Yuqing Zhang⁴, Christine Peloquin⁵, Tuhina Neogi⁴, Hyon K. Choi² and David T. Felson⁶, ¹Rheumatology, Boston Medical Center, Boston, MA, ²Rheumatology, Boston University School of Medicine, Boston, MA, ³Rheumatology, VA Boston Healthcare System, Jamaica Plain, MA, ⁴Boston University School of Medicine, Boston, MA, ⁵Clinical Epidemiology Research & Training Unit, Boston University School of Medicine, Boston, MA, ⁶Clinical Epidemiology Unit, Boston University School of Medicine, Boston, MA
Background/Purpose: Certain non-steroidal anti-inflammatory drugs (NSAIDs) have been associated with an increased risk of myocardial infarction (MI). MI risk for different NSAIDs varies largely because…
Abstract Number: 821 • 2014 ACR/ARHP Annual Meeting
Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update
Christina D Chambers^1,2, Diana L Johnson¹, Yunjun Luo¹, Ronghui Xu^2,3 and Kenneth L Jones¹, ¹University of California San Diego Department of Pediatrics, La Jolla, CA, ²University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, ³University of California San Diego Department of Mathematics, La Jolla, CA
Background/Purpose Adalimumab is a fully human monoclonal antibody to tumor necrosis factor alpha and is approved for several indications including rheumatoid arthritis (RA). Methods The…
Abstract Number: 820 • 2014 ACR/ARHP Annual Meeting
Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination
Huifeng Yun¹, Shuo Yang², Lang Chen³, Fenglong Xie⁴, Kevin L. Winthrop⁵, John Baddley³, Kenneth G. Saag⁶, Jasvinder A. Singh⁷ and Jeffrey R. Curtis⁸, ¹Epidemiology, University of Alabama at Birmingham School of Public Health, Birmingham, AL, ²Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁴Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ⁵Division of Infectious Diseases, Oregon Health and Science University, Portland, OR, ⁶Immunology & Rheumatology, The University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL, ⁸Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Herpes zoster (HZ) vaccine is recommended for healthy people age >= 60 years in US. It is unclear whether the absolute risk for younger…
Abstract Number: 839 • 2014 ACR/ARHP Annual Meeting
Cardiovascular Risk with Nsaids in Rheumatoid Arthritis: An Analysis Using Routinely Collected Data
Fowzia Ibrahim¹, Antigoni Grigoriou^1,2, Khaldoun Chaabo^1,2, David L. Scott^1,2, Sophia Steer^1,2 and James Galloway^1,2, ¹King's College London, Department of Rheumatology, London, United Kingdom, ²King's College Hospital, Department of Rheumatology, London, London, United Kingdom
Background/Purpose Atherosclerotic disease increases the morbidity and mortality in Rheumatoid Arthritis (RA). NSAIDs are associated with Cardiovascular (CV) risk in the general population. Data from…
Abstract Number: 838 • 2014 ACR/ARHP Annual Meeting
The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare?
Elena Myasoedova¹, Arun K. Chandran², Birkan İlhan³, Brittny T. Major⁴, C. John Michet III², Eric L. Matteson² and Cynthia S. Crowson⁴, ¹Internal Medicine and Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Department of Internal Medicine, Marmara University School of Medicine, Istanbul, Turkey, ⁴Health Sciences Research, Mayo Clinic, Rochester, MN
Background/Purpose Patients with rheumatoid arthritis (RA) are at increased risk of cardiovascular disease (CVD). Longitudinal studies assessing the effect of changes of RA activity on…
Abstract Number: 837 • 2014 ACR/ARHP Annual Meeting
Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab
Eamonn Molloy¹ and Leonard H. Calabrese², ¹St Vincent University Hospital, Dublin, Ireland, ²Rheumatic & Immunologic Dis, Cleveland Clinic Foundation, Cleveland, OH
Background/Purpose Progressive Multifocal Leukoencephalopathy (PML) is a rare and often fatal opportunistic infection recently associated with several biologic therapies. However, ascribing risk to individual therapies…
Abstract Number: 836 • 2014 ACR/ARHP Annual Meeting
Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years
Aryeh Fischer¹, Virginia D. Steen², Steven Nathan³, Hunter Gillies⁴, James Tislow⁵ and Chris Blair⁶, ¹Rheumatology / ILD Program, National Jewish Health, Denver, CO, ²Department of Rheumatology, Georgetown University Medical Center, Washington, DC, ³Heart Failure/Transplant, Inova Medical Group, Falls Church, VA, ⁴Clinical Research - Cardiovascular, Gilead Sciences, Inc., Foster City, CA, ⁵Medical Affairs, Gilead Sciences, Inc., Foster City, CA, ⁶Biostatistics, Gilead Sciences, Inc., Foster City, CA
Background/Purpose: The 6MWD is a valuable tool for evaluating response to therapy in patients with pulmonary arterial hypertension and may be considered a surrogate measure…
Abstract Number: 835 • 2014 ACR/ARHP Annual Meeting
Relapsing Polychondritis Can be Characterized By 3 Different Clinical Phenotypes: Analysis of a Series of 142 Patients
Jeremie Dion¹, Nathalie Costedoat-Chalumeau¹, Damien Sène², Judith Cohen-Bittan³, Gaëlle Leroux⁴, Charlotte Dion⁵, Camille Francès⁶ and Jean-Charles Piette⁷, ¹Internal medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ²Hopital Lariboisière, service de Médecine Interne, Paris, France, ³Service de medecine gériatrique, CHU Pitié-Salpêtrière, Paris, France, ⁴Department of Internal Medicine 1, CHU Pitié-Salpêtrière, Paris, France, ⁵Ecole des hautes études en sciences sociales, Paris, France, ⁶service de dermatologie allergologie, Hôpital Tenon, Paris Cedex 20, France, ⁷Department of Internal Medicine 1., CHU Pitié-Salpêtrière, Paris, France
Background/Purpose We previously described clinical characteristics and evolution of 142 patients with relapsing polychondritis (RP) followed in a single center and seen at least once…
Abstract Number: 834 • 2014 ACR/ARHP Annual Meeting
Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still’s Disease and Systemic Onset Juvenile Idiopathic Arthritis
Holger Kudela¹, Susanne Drynda², Anke Lux³, Gerd Horneff⁴ and Joern Kekow², ¹Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, ²Clinic of Rheumatology, Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, ³Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, ⁴Pediatrics, Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany
Background/Purpose: Establishing the diagnosis of adult onset Still’s disease (AOSD) as well as of systemic onset juvenile idiopathic arthritis (sJIA) is very challenging. Mostly it…
Abstract Number: 833 • 2014 ACR/ARHP Annual Meeting
Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry
Hal M. Hoffman¹, Jasmin B. Kuemmerle-Deschner², Philip N. Hawkins³, T. van der Poll⁴, Ulrich A. Walker⁵, Ken Abrams⁶ and Hugh H. Tilson⁷, ¹Division of Allergy, Immunology and Rheumatology, University of California at San Diego, La Jolla, CA, ²University Hospital Tuebingen, Tuebingen, Germany, ³University College London Medical School, London, United Kingdom, ⁴Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, ⁵Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, ⁶Novartis Pharmaceutical Corporation, East Hanover, NJ, ⁷Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
Background/Purpose The three phenotypes in the order of severity: familial cold auto-inflammatory syndrome (FCAS), Muckle-Wells syndrome (MWS), and chronic infantile neurologic cutaneous and articular syndrome/neonatal…
Abstract Number: 832 • 2014 ACR/ARHP Annual Meeting
NOD2-Associated Autoinflammatory Disease: The Largest Cohort Study
Qingping Yao¹, Min Shen², Christine McDonald³, Felicitas Lacbawan⁴ and Bo Shen⁵, ¹Rheumatic and Immunologic Dis, Cleveland Clinic, Cleveland, OH, ²Rheumatic and Immunologic Disease, Cleveland Clinic, Cleveland, OH, ³Pathobiology, Cleveland Clinic, Cleveland, OH, ⁴Molecular Genetics Pathology, Cleveland Clinic, Cleveland, OH, ⁵Gastroenterology, Cleveland Clinic, Cleveland, OH
Background/Purpose NOD2-associated autoinflammatory disease (NAID) is an emerging systemic inflammatory disease. The aim is to report our extended study of the phenotypic and genotypic features of…
Abstract Number: 811 • 2014 ACR/ARHP Annual Meeting
Biologics in Takayasu Arteritis: Preliminary Data from the French Registry
Arsene Mekinian¹, Chloe Comarmond², Mathieu Resche Regon³, Tristan Mirault⁴, Jean-Emmanuel Kahn⁵, Marc Lambert⁶, Jean Sibilia⁷, Antoine Neel⁸, Miguel Hié⁹, Emmanuel Messas¹⁰, Pascal Cohen¹¹, Geraldine Muller¹², Sabine Berthier¹³, Zahir Amoura¹⁴, Isabelle Marie¹⁵, Christian Lavigne¹⁶, Marie Anne Vandenhende¹⁷, Hervé Devilliers¹⁸, Sébastien Abad¹⁹, Loic Guillevin²⁰, Mohamed Hamidou²¹, Bertrand Godeau²², Patrice Cacoub²³, Olivier Fain²⁴ and David Saadoun², ¹DHU2iB, Internal Medicine Saint Antoine Hospital, PARIS, France, ²DHU 2iB Internal Medicine Referal Center for Autoimmune diseases Pitie Hospital, Paris, France, ³biostatistics Saint Louis Hospital, paris, France, ⁴HEGP vascular department, paris, France, ⁵Internal Medicine, Foch Hospital, Suresnes, France, ⁶Faculté de Médecine Henri Warembourg, Université Lille Nord de France, Lille, France, ⁷Division of Rheumatology, University Hospital of Strasbourg, Strasbourg, France, ⁸INTERNAL MEDICINE, NANTES, France, ⁹Hôpital Pitié-Salpêtrière, AP-HP, UPMC Univ Paris 06 & French National Reference Center For Systemic Lupus and Antiphospholipid Syndrome, Paris, France, ¹⁰HEGP hospital Vascular and cardiology Department, paris, France, ¹¹National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ¹²INTERNAL MEDICINE, DIJON, France, ¹³DIJON HOSPITAL, DIJON, France, ¹⁴Internal medicine 2, French National Reference Center for Systemic Lupus and Antiphospholipid Syndrome, Pitié-Salpêtrière Hospital (AP-HP), Paris, France, ¹⁵CHU de Rouen, Rouen, France, ¹⁶CHU d'Angers, Angers, France, ¹⁷Internal Medicine, Bordeaux, France, ¹⁸Dijon University Hospital, Department of internal medicine and systemic diseases, Dijon, France, ¹⁹Hôpital Avicenne, Bobigny, France, ²⁰Internal Medicine, Service de médecine interne, Centre de Références des Vascularites, Université Paris Descartes, APHP, Hôpital Cochin, 75005 Paris, France., Paris, France, ²¹CHU Hôtel Dieu, Nantes, Nantes, France, ²²Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Service de médecine interne, Université Paris Est Créteil, AP-HP, Hôpital Mondor Créteil, France, Creteil, France, ²³Groupe Hospitalier Pitié Salpétrière, Service de Médecine Interne, DHU i2B, Paris, France, ²⁴Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France
Background/Purpose The aim of this registry is to determine: (1) the real-life use of various biological targeted treatments in Takayasu arteritis (TA) in France; (2)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].